An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa

Trial Profile

An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Mycophenolate mofetil (Primary) ; Cyclophosphamide
  • Indications Periarteritis nodosa
  • Focus Therapeutic Use
  • Acronyms MYPAN
  • Most Recent Events

    • 04 Nov 2015 Accrual to date is 7% according to United Kingdom Clinical Research Network.
    • 16 Apr 2015 Accrual to date is 5% according to United Kingdom Clinical Research Network.
    • 17 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top